The concern of generic rivalry has consistently loomed over copyright’s famous drug, PDE5 Inhibitor, raising questions about the future of similar medicinal stakes. While initial times saw significant profits, the patent end has created the path for discounted copies, potentially lowering revenue and creating a significant risk for shareholders l